PureTech Advances LYT-100 into Phase 3 Clinical Trial Following FDA Feedback
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Source: Newsfilter
- Positive FDA Feedback: PureTech successfully completed an End-of-Phase 2 meeting with the FDA, laying the groundwork for the Phase 3 SURPASS-IPF trial of LYT-100, expected to initiate in the first half of 2026, showcasing the company's strong potential in treating idiopathic pulmonary fibrosis (IPF).
- Optimized Trial Design: The Phase 3 trial will compare LYT-100 at 825 mg TID against pirfenidone at 801 mg TID, with the primary endpoint assessing changes in forced vital capacity (FVC) at 52 weeks, aiming to validate LYT-100's superiority and establish it as a new standard of care.
- Clinical Data Support: In the Phase 2b ELEVATE IPF trial, LYT-100 demonstrated significant lung function improvement, with a decline rate of -21.5 mL at 26 weeks compared to -112.5 mL in the control group, indicating its effectiveness in slowing disease progression.
- Clear Financing Plans: Celea Therapeutics expects to finalize financing in early 2026 to support the initiation of the Phase 3 trial, paving the way for LYT-100's commercialization and further enhancing PureTech's competitiveness in the biotherapeutics sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRTC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRTC
About PRTC
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Robert Lyne Appointed CEO of PureTech
- New CEO Appointment: PureTech Health has appointed Robert Lyne as the new chief executive officer.
- Announcement Date: The announcement regarding the appointment was made on Thursday.
Continue Reading
PureTech Appoints Robert Lyne as CEO, Focuses on Funding and Innovation
- Leadership Change: PureTech Health plc appoints Robert Lyne as CEO, aiming to leverage his extensive experience in the biotech sector to drive the company's strategic development in innovation and funding.
- Funding Plans: The company plans to secure funding for its newly founded entity, Celea Therapeutics, by the first half of 2026, which is expected to significantly reduce operational costs and enhance shareholder value.
- Capital Efficiency Improvement: Lyne emphasizes a streamlined operational structure and a disciplined investment strategy to ensure efficient capital utilization while advancing key innovation initiatives.
- Strategic Focus: The new CEO will concentrate on optimizing shareholder returns, with plans to evaluate potential capital return methods after Celea is fully financed, ensuring sustained growth in the biopharmaceutical sector.
Continue Reading